Archivi categoria: POST TKI

KEYNOTE-789

STUDY OF PEMETREXED + PLATINUM CHEMOTHERAPY WITH OR WITHOUT PEMBROLIZUMAB (MK-3475) IN ADULTS WITH TYROSINE KINASE INHIBITOR- (TKI)-RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR- (EGFR)-MUTATED METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

STADIO
IV

Il protocollo è attivo nei seguenti centri

Scopri





OSIRIS

(OSIMERTINIB RECHALLENGE TKI IN SUBSEQUENT LINE OF THERAPY) A PHASE II, NONCOMPARATIVE, OPEN LABEL, MULTICENTRE, STUDY OF AZD9291 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EGFR MUTATED “T790M UNDETECTABLE OR UNKNOWN” NON-SMALL CELL LUNG CANCER (STAGE IIIB-IV) AFTER NO IMMEDIATE PRIOR EGFR TKI

STADIO
IIIB/IV

Il protocollo è attivo nei seguenti centri

Scopri